BMS-CTMC-2024-32: Personalized Oncology, Platforms and Selection

Da-Yong Lu and Ting-Ren Lu

School of Life Sciences, Shanghai University

^*Correspondance to: Da-Yong Lu 

 PDF  Full Text Review Article | Open Access

Abstract:

Cancer is a complex and high-mortality disease caused by different kinds of risk-factors, hallmarks and pathogenesis stages. Personalized Oncology (PO) or Precision Medicine (PM) is adapted for drugs elections against various oncogenic pathways and hallmarks. After six-decade development, personalized oncology has been evolving into various platforms in the clinic. However, greater therapeutic benefits should be based on correct selection of platforms and technique advances. Next generation of PO will simultaneously contain information of pharmacology (drug sensitivity or drug combination), oncology (genomic sequencing, multi-omics profiling, computation, biomarkers and response scores) and toxicology (adverse side-effects and human mortality). Unlimited technical advances can greatly increase therapeutic benefits of cancer treatments. Integration and balances of different techniques might take a leading-position in the future. A reliable, safe, effective and integrative platform will be accomplished by different scientific and technical approaches.

Keywords:

Personalized oncology; Precision medicine; Drug selection; Artificial intelligence; Diagnostic platforms; Computational network; Single-cell multi-omics; Cancer metastasis

Cite the Article:

Da-Yong Lu and Ting-Ren Lu. BMS-CTMC-2024-32: Personalized Oncology, Platforms and Selection. Clin Oncol. 2024;9:2105..